קלונקס

האם יכול להיות שבזמן שהקלונקס בשיא השפעתו 3 שעות אחרי נטילתו פתאום כשנוספה בעיה חדשה זה פתאום חזר שוב וכעבור שעה מבלי ליטול עוד כדור זה שוב נרגע אז מה משפיע יותר האם אני שולטת בזה ואז אולי לא צריך לקחת בכלל אלא לנסות להתגבר אבל מהנסיון זה לא פשוט להתגבר לבד,מה גם שהקלונקס לא פותרת את כל הבעיה ותמיד קיים החשש שהמחשבות והניתוק קיימים.

לרוני מזל שהקלונקס אינה תרופה כל כך חזקה שמכסה והופכת אותנו לאדישים לגמרי. לכן ישנה חרדה שהקלונקס פותרת אותה לחלוטין, אם החרדה גבוהה מדי השפעת הקלונקס היא חלקית. החוכמה היא למצוא את שביל הזהב, לנסות להתגבר ולא ליטול קלונקס, אבל גם לא להתאפק יותר מדי ולסבול יותר מדי. כל יום וכל אדם לפי מצבו באותו הרגע. שיהיה רק טוב דר' גיורא הידש

Antiepileptic drug; also used as tranquilizer AND anxiolytic. Has been studied in the treatment of tardive dyskinesia, delirium tremens, restless legs AND manic states. Terminal plasma half-life in healthy subjects 19 up to 30 hours. Studied in treatment of panic disorders. Presents advantages over other BDZ AND has been claimed as a first-line agent for panic disorder. Studied in high doses (8-12mg/d) in mania. Rapid onset of action but severe side-effects. Potential use in the treatment of neuroleptic-induced akathisia at an optimal daily dose in the range of 10-40mg. Indication: atomic AND myoclonic seizures atypical absence seizures resistant to ethosuximide AND valproic acid: infantile spasms. WHO Drug Information 11/1: 25, 1997. Studied in high doses (8-12mg/d) in mania. Rapid onset of action but severe side-effects. Potential use in the treatment of neuoleptic-induced akathisia at an optimal daily dose in the range of 10-40mg. The addition of clonazepam to fluoxetine during the first weeks of treatment of depression may reduce suffering during early SSRI treatment, partially supress SSRI side effects, increase compliance, AND possibly reduce the suicidal risk. Japanese clinicians reported the positive results obtained with an adjunctive dose of clonazepam (at least 3mg/d) in patients with prolonged depression. Successful for the treatment for all types of the drugs AND alcohol withdrawal symptoms. It is hypothized that this effect is linked with the connection between BDZ receptors AND the other, mainly opiate receptors. Effective AND safe short-term treatment of the panic disorder symptoms.

Antiepileptic drug; also used as tranquilizer AND anxiolytic. Has been studied in the treatment of tardive dyskinesia, delirium tremens, restless legs AND manic states. Terminal plasma half-life in healthy subjects 19 up to 30 hours. Studied in treatment of panic disorders. Presents advantages over other BDZ AND has been claimed as a first-line agent for panic disorder. Studied in high doses (8-12mg/d) in mania. Rapid onset of action but severe side-effects. Potential use in the treatment of neuroleptic-induced akathisia at an optimal daily dose in the range of 10-40mg. Indication: atomic AND myoclonic seizures atypical absence seizures resistant to ethosuximide AND valproic acid: infantile spasms. WHO Drug Information 11/1: 25, 1997. Studied in high doses (8-12mg/d) in mania. Rapid onset of action but severe side-effects. Potential use in the treatment of neuoleptic-induced akathisia at an optimal daily dose in the range of 10-40mg. The addition of clonazepam to fluoxetine during the first weeks of treatment of depression may reduce suffering during early SSRI treatment, partially supress SSRI side effects, increase compliance, AND possibly reduce the suicidal risk. Japanese clinicians reported the positive results obtained with an adjunctive dose of clonazepam (at least 3mg/d) in patients with prolonged depression. Successful for the treatment for all types of the drugs AND alcohol withdrawal symptoms. It is hypothized that this effect is linked with the connection between BDZ receptors AND the other, mainly opiate receptors. Effective AND safe short-term treatment of the panic disorder symptoms.